NBIX vs. ANIP
NBIX (Neurocrine Biosciences, Inc.) and ANIP (ANI Pharmaceuticals, Inc.) are both stocks. Both operate in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Over the past 10 years, NBIX returned 13.16%/yr vs 4.07%/yr for ANIP. At a 0.20 correlation, their price movements are largely independent.
Performance
NBIX vs. ANIP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, NBIX achieves a 12.64% return, which is significantly higher than ANIP's 3.47% return. Over the past 10 years, NBIX has outperformed ANIP with an annualized return of 13.16%, while ANIP has yielded a comparatively lower 4.07% annualized return.
NBIX
- 1D
- -1.81%
- 1M
- -0.97%
- YTD
- 12.64%
- 6M
- 4.55%
- 1Y
- 27.80%
- 3Y*
- 18.64%
- 5Y*
- 10.13%
- 10Y*
- 13.16%
ANIP
- 1D
- 0.04%
- 1M
- 0.99%
- YTD
- 3.47%
- 6M
- 1.60%
- 1Y
- 31.49%
- 3Y*
- 18.03%
- 5Y*
- 18.57%
- 10Y*
- 4.07%
NBIX vs. ANIP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
NBIX Neurocrine Biosciences, Inc. | 12.64% | 3.90% | 3.60% | 10.31% | 40.24% | -11.14% | -10.83% | 50.53% | -7.96% | 100.49% |
ANIP ANI Pharmaceuticals, Inc. | 3.47% | 42.80% | 0.25% | 37.06% | -12.70% | 58.68% | -52.91% | 36.98% | -30.15% | 6.32% |
Correlation
The correlation between NBIX and ANIP is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.21 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.27 |
Correlation (All Time) Calculated using the full available price history since May 5, 2000 | 0.20 |
Fundamentals
NBIX:
$16.52B
ANIP:
$1.76B
NBIX:
$6.53
ANIP:
$4.26
NBIX:
24.46
ANIP:
19.17
NBIX:
0.48
ANIP:
0.13
NBIX:
5.27
ANIP:
1.86
NBIX:
4.85
ANIP:
3.13
NBIX:
$3.10B
ANIP:
$923.71M
NBIX:
$3.05B
ANIP:
$486.11M
NBIX:
$881.20M
ANIP:
$234.71M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
NBIX vs. ANIP — Risk / Return Rank
NBIX
ANIP
NBIX vs. ANIP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and ANI Pharmaceuticals, Inc. (ANIP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NBIX | ANIP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | 0.00 | ||
| Sortino ratioReturn per unit of downside risk | -0.31 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.19 | 0.00 |
| Calmar ratioReturn relative to maximum drawdown | 1.34 | 1.10 | +0.23 |
| Martin ratioReturn relative to average drawdown | 2.94 | 2.06 | +0.88 |
Loading charts...
Drawdowns
NBIX vs. ANIP - Drawdown Comparison
The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum ANIP drawdown of -98.81%. Use the drawdown chart below to compare losses from any high point for NBIX and ANIP.
Loading charts...
Drawdown Indicators
| NBIX | ANIP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.21% | -98.81% | +1.60% |
Max Drawdown (1Y)Largest decline over 1 year | -20.90% | -28.66% | +7.76% |
Max Drawdown (3Y)Largest decline over 3 years | -42.89% | -28.66% | -14.23% |
Max Drawdown (5Y)Largest decline over 5 years | -42.89% | -59.38% | +16.49% |
Max Drawdown (10Y)Largest decline over 10 years | -46.39% | -72.96% | +26.57% |
Current DrawdownCurrent decline from peak | -4.54% | -81.85% | +77.31% |
Average DrawdownAverage peak-to-trough decline | -43.84% | -79.39% | +35.55% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.49% | 15.33% | -5.84% |
Volatility
NBIX vs. ANIP - Volatility Comparison
Neurocrine Biosciences, Inc. (NBIX) has a higher volatility of 9.63% compared to ANI Pharmaceuticals, Inc. (ANIP) at 9.14%. This indicates that NBIX's price experiences larger fluctuations and is considered to be riskier than ANIP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| NBIX | ANIP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.63% | 9.14% | +0.49% |
Volatility (6M)Calculated over the trailing 6-month period | 23.91% | 24.38% | -0.47% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.38% | 35.56% | -4.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.73% | 46.29% | -13.56% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 39.13% | 48.26% | -9.13% |
Dividends
NBIX vs. ANIP - Dividend Comparison
Neither NBIX nor ANIP has paid dividends to shareholders.
Financials
NBIX vs. ANIP - Financials Comparison
This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and ANI Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
NBIX vs. ANIP - Profitability Comparison
NBIX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a gross profit of 800.70M and revenue of 814.50M. Therefore, the gross margin over that period was 98.3%.
ANIP - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 237.46M. Therefore, the gross margin over that period was 0.0%.
NBIX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported an operating income of 193.40M and revenue of 814.50M, resulting in an operating margin of 23.7%.
ANIP - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported an operating income of 38.89M and revenue of 237.46M, resulting in an operating margin of 16.4%.
NBIX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Neurocrine Biosciences, Inc. reported a net income of 197.90M and revenue of 814.50M, resulting in a net margin of 24.3%.
ANIP - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ANI Pharmaceuticals, Inc. reported a net income of 29.49M and revenue of 237.46M, resulting in a net margin of 12.4%.
Frequently Asked Questions
NBIX and ANIP have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
NBIX has higher volatility (9.63%) compared to ANIP (9.14%). In terms of maximum drawdown, NBIX dropped -97.21% vs ANIP's -98.81%.
ANIP currently has the higher Sharpe Ratio (0.89 vs 0.89), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for NBIX and ANIP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer